Senaste uppdateringen :
03/05/2024
Cancerläkemedel   Docetaxel  
Injektion
Lösningars stabilitet Stabilitet i blandningar Faktorer som påverkar stabiliteten Kompatibilitet Administreringssätt Hänvisningar Pdf
   Molekylstruktur  

Varunamn   Varunamn     

Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare

Adenex Colombia
Asodocel Argentina
Axogen Chile
Bagotaxel Chile
Bendadocel Tyskland
Brecasta Chile
Celtere Peru
Daxotel Chile, Colombia, Egypten, Malaysia
Doce NC Tyskland
Docefrez Förenta Staterna, Indien
Docekebir Argentina
Docetax Iran, Venezuela
Docetaxin Tyskland
Docewin Marocko
Dolectran Argentina
Donataxel Argentina, Ecuador, Peru
Doxel Turkiet, Venezuela
Doxetal Argentina
Doxitax Turkiet
Oncodocel Colombia, Peru
Onkotaxel Colombia, Österrike
Ribodocel Tyskland
Santax Turkiet
Tadocel Turkiet
Taxceus Storbritannien
Taxotan Tyskland
Taxotere Argentina, Australien, Belgien, Chile, Colombia, Danmark, Ecuador, Egypten, Finland, Förenade Arabemiraten, Förenta Staterna, Frankrike, Grekland, Iran, Island, Italien, Japan, Kanada, Kroatien, Luxemburg, Malaysia, Marocko, Mexiko, Nederländerna, Norge, Nya Zeeland, Österrike, Polen, Portugal, Rumänien, Saudi-Arabien, Schweiz, Spanien, Storbritannien, Sverige, Thailand, Tunisien, Turkiet, Tyskland, Ungern, Venezuela
Texot Argentina
Tolnexa Rumänien
Zenotere Indien, Peru
Hänvisningar   Injektion   Hänvisningar : Docetaxel  
Typ Publikation
140 Tidningen Pearson SD, Trissel LA.
Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components.
Am J Hosp Pharm 1993 ; 50: 1405-1409.
250 Tidningen Mazzo DJ, Nguyen-Huu JJ, Pagniez S, Denis P.
Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials.
Am J Health-Syst Pharm 1997 ; 54: 566-569.
251 Tidningen Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
1423 Tidningen Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1660 Tidningen Thiesen J, Krämer I.
Physico-chemical stability of docetaxel premix solution and docetaxel infusion solutions in PVC bags and polyolefine containers.
Pharm World Sci 1999 ; 21: 137-141.
1662 Tidningen Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1754 Tidningen Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1940 Tidningen Xu QA, Trissel LA.
Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 1596-1598.
1953 Tidningen Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 Tidningen Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2175 Tidningen Dalle M, Sautou-Miranda V, Balayssac D, Bourlon S, Bagel S, Chopineau J.
Peut-on conditionner les solutions de docétaxel dans des poches en PVC ?
J Pharm Clin 2006 ; 25, 3: 147-152.
2210 Tidningen Walker S.E, Charbonneau F, Law S.
Stability of Docetaxel Solution after Dilution in Ethanol and Storage in Vials and after Dilution in Normal Saline and Storage in Bags.
Can J Hosp Pharm 2007 ; 60, 4: 231-237.
2262 Tidningen Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2341 Affisch Bourlon S, Sautou-Miranda V, Dalle M.
Release of di(2-ethylhexyl)phtalate from polyvinylchloride bags during docetaxel infusions
Poster ESCP Stockholm May 2005
3130 Laboratorium Docétaxel (Taxotere®) – Résumé des caractéristiques du produits
Sanofi Avantis France 2009
3163 Tidningen Acott SR, Hart M.
Physical and chemical stability of Taxotere 1-vial 20mg/mL infusion solution following refrigerated storage.
EJHP 2010 ; 16, 5: 26-28.
3195 Tidningen MacLeod S, Sewell G.
Physical and chemical stability of docetaxel infusions.
EJHP 2011 ; 17, 2: 39-43.
3215 Tidningen Hart MC, Ahmed W.
Taxotere 1-vial (docetaxel 20 mg/ml) physical and chemical stability over 28 days in infusion bags containing 0.9% saline solution and 5% glucose solution.
EJOP 2011 ; 5,1: 24-27.
3277 Tidningen Yang Z, Cameron S, Paul H.
Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration.
Int J Pharm Compound 2012 ; 16, 1 : 82-85.
3804 Tidningen Lazzarini R, Salvadori S, Trapella C, Guerrini R, Marzola E, Pasini G, Dalpiaz A.
Physicochemical stability of cabazitaxel and docetaxel solutions.
EJHP 2014 ;22:150-155.
3937 Tidningen Park K.H, Chung D.J.
Stability study of docetaxel solution (0.9% saline) using Non-PVC and PVC tubes for intravenous administration.
Biomat Res 2015 ; 19, 2

  Mentions Légales